ArticleBMC biotechnology2025
FOXK1 regulates apoptosis, migration and angiogenesis in high glucose-induced vascular endothelial cells through p-AKT/AKT signaling pathway.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- IDH2 deficiency enhances ferroptosis-induced vascular inflammation and remodeling in diabetes.Scientific reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundForkhead box K1 (FOXK1) is a newly discovered gene encoding a transcription factor in the FOX family. It plays important roles in the cell cycle, cell growth, proliferation, differentiation, apoptosis, metabolism, DNA damage, drug resistance, angiogenesis, and carcinogenesis by binding to DNA to function as a transcription factor. Many studies have confirmed that FOXK1 plays a role in promoting cancer in a variety of tumors. However, the pathogenic role of FOXK1 in diabetic retinopathy (DR) is still unclear. The present study was conducted to investigate the mechanism of FOXK1 in the vascular endothelial dysfunction of DR.
methodsHuman umbilical vein endothelial cells (HUVECs) were exposed to high glucose (HG) concentrations (25 mmol/L) to establish a vascular endothelial dysfunction model of DR. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the differential expression of FOXK1 in HUVECs treated with HG and low glucose (LG). CCK-8, Transwell, flow cytometry and tube formation assays were used to investigate the effect of FOXK1 on HUVECs function. To explore the downstream signaling pathway of FOXK1, Western blotting was subsequently used to detect the protein expression of p-AKT and AKT after FOXK1 was knocked down in HUVECs. The AKT inhibitor MK-2206 was used to treat HUVECs, and cell migration, apoptosis and angiogenesis were observed.
resultsThe results showed that FOXK1 expression was significantly increased in HUVECs cultured with high glucose. In this endothelial dysfunction model, knockdown of FOXK1 increased HUVECs activity and migration, inhibited HUVECs apoptosis, angiogenesis and VEGF expression, and activated the p-AKT/AKT signaling pathway. All of these were reversed by the AKT inhibitor MK-2206.
conclusionsFOXK1 may mediate vascular endothelial dysfunction in DR by inhibiting p-AKT/AKT pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.